← Eichor
Study identifier: NCT06900595 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Condition: Locally Advanced Adrenal Cortical Carcinoma · Metastatic Adrenal Cortical Carcinoma · Recurrent Adrenal Cortical Carcinoma  ·  Sponsor: National Cancer Institute (NCI)

PhasePhase 2
Planned participants48
Who can joinAll sexes, 12 Years to no upper limit
Healthy volunteersNo

About this study

This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with cemiplimab may kill more tumor cells in patients with locally advanced unresectable or recurrent/metastatic adrenocortical cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (77)

UC San Diego Moores Cancer CenterLa Jolla, California, United StatesRecruiting
Valley Children's HospitalMadera, California, United StatesRecruiting
UCHealth University of Colorado HospitalAurora, Colorado, United StatesRecruiting
Lurie Children's Hospital-ChicagoChicago, Illinois, United StatesRecruiting
Northwestern UniversityChicago, Illinois, United StatesRecruiting
Carle at The RiverfrontDanville, Illinois, United StatesRecruiting
Northwestern Medicine Cancer Center KishwaukeeDeKalb, Illinois, United StatesRecruiting
Carle Physician Group-EffinghamEffingham, Illinois, United StatesRecruiting
Northwestern Medicine Cancer Center DelnorGeneva, Illinois, United StatesRecruiting
Northwestern Medicine Glenview Outpatient CenterGlenview, Illinois, United StatesRecruiting
Northwestern Medicine Grayslake Outpatient CenterGrayslake, Illinois, United StatesRecruiting
Northwestern Medicine Lake Forest HospitalLake Forest, Illinois, United StatesRecruiting

+ 65 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06900595